Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123593 | 0.84 | POLB (0.49) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12877465 | 0.82 | TGFBR1 (0.42) | NPC1RAB9AADORA1KDM4EALDH1A1 | |
| SCHEMBL15134752 | 0.82 | NISCH (0.41) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11983462 | 0.81 | NPC1 (0.50) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12877694 | 0.80 | MAPK1 (0.41) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL16509738 | 0.80 | BTK (0.47) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL384952 | 0.79 | NPC1 (0.61) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20163117 | 0.79 | NPC1 (0.48) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28952654 | 0.79 | NPC1 (0.48) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16637043 | 0.78 | NPC1 (0.49) | POLBNPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070208064-A1 | Ion channel modulators | WYETH (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208064-A1 | Ion channel modulators | WYETH (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2005087228-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | L3MBTL1 3558/4885POLB 4663/4885NPC1 325/4885 |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1C, CACNA1D, CACNA1G | L3MBTL1 1169/4885POLB 4760/4885NPC1 2407/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | L3MBTL1 4349/4885POLB 4203/4885NPC1 3670/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | L3MBTL1 3042/4885POLB 334/4885NPC1 512/4885 |
| US-20070208064-A1 | Ion channel modulators | CACNA1B, CACNA1C, TRPV1 | L3MBTL1 3558/4885POLB 4663/4885NPC1 325/4885 |
| US-20080090891-A1 | ION CHANNEL MODULATORS | CACNA1B, CACNA1C, TRPV1 | L3MBTL1 3558/4885POLB 4663/4885NPC1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.